Sensei Biotherapeutics, Inc. Stock Price, News & Analysis

Sensei Biotherapeutics (NASDAQ: SNSE) presented promising data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference. Preclinical results indicate SNS-101 enhances anti-tumor effects when combined with anti-PD-1 antibodies, achieving five complete responses in a resistant tumor model. The antibody also exhibits a favorable pharmacokinetic profile, reducing the risk of cytokine release syndrome compared to traditional VISTA antibodies. This data may support SNS-101's potential for broad oncological applications.

Sensei Biotherapeutics (Nasdaq: SNSE) announced it will present new preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference in New York from September 28 to October 1, 2022. The poster presentation is scheduled for September 30, highlighting SNS-101's favorable pharmacokinetic properties and its potential to enhance anti-PD-1 responses. This aligns with Sensei's mission of developing next-generation cancer therapeutics.

Sensei Biotherapeutics (NASDAQ: SNSE) announced preliminary preclinical data for SNS-101, an antibody targeting the VISTA immune checkpoint. Results indicate that SNS-101 effectively overcomes pharmacokinetic challenges and enhances anti-tumor effects when combined with anti-PD-1 antibodies. Additionally, SNS-101 shows a favorable pharmacokinetic profile, with a median half-life of approximately three weeks. Ongoing IND-enabling studies aim to evaluate SNS-101's potential for treatment in solid cancers, with an IND filing planned for the first half of 2023.

Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in two key investor conferences in September 2022, aimed at exploring the latest in immuno-oncology developments.

The conferences are:

• Citi’s 17th Annual Biopharma Conference (September 7-8, Boston, MA)
• Wells Fargo’s 2022 Healthcare Conference (September 7-9, Boston, MA)

Interested portfolio managers and analysts can arrange meetings with company management through their respective representatives.

Sensei Biotherapeutics (NASDAQ: SNSE) announced progress in its clinical programs, including pre-IND feedback from the FDA for SNS-101, an anti-VISTA antibody, expected to file an IND in the first half of 2023. The company will present new pharmacokinetic data in non-human primates in Q3 2022. The strong financial position, with cash equivalents of $123.7 million, supports operations through Q1 2025. Research and development expenses increased to $6.4 million due to higher headcount and inflation. The net loss was reported at $10.5 million for Q2 2022.

On June 1, 2022, Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Patrick Gallagher as Chief Business Officer. Gallagher, an experienced biotech executive, will leverage his nearly 20 years in the pharmaceutical and biotech sectors to enhance Sensei's strategic initiatives. His past roles include significant contributions to various reputable companies and investment banking firms. This leadership change is expected to strengthen the company's position during critical phases of program advancements.

Sensei Biotherapeutics, a leader in immunotherapy, announced that CEO John Celebi will present at the Jefferies Healthcare Conference on June 8, 2022, at 3:00 p.m. ET, both in-person and virtually in New York, NY. Investors can access a live webcast of the presentation on the company's website, with a replay available for 90 days afterward. Sensei focuses on developing innovative cancer therapies, utilizing its TMAb™ and ImmunoPhage™ platforms. Their lead therapeutic candidate, SNS-101, targets the VISTA checkpoint to enhance T cell activity in the tumor microenvironment.

Sensei Biotherapeutics (SNSE) reported Q1 2022 financial results, highlighting a net loss of $12.4 million, up from $8.0 million in Q1 2021. The company's cash reserves stood at $136.2 million, sufficient to fund operations through Q1 2025. Progress on the TMAb™ platform includes promising preclinical data for SNS-101, an anti-VISTA antibody targeting solid tumors, which showed selective binding in low pH environments. The firm also anticipates submitting an IND for SNS-101 in the first half of 2023 following successful GMP manufacturing initiation.

Sensei Biotherapeutics (NASDAQ: SNSE) announced significant advancements in its pipeline with the initiation of new therapeutic programs, including SNS-101, an anti-VISTA antibody. The company reported a strong cash position of $147.6 million as of December 31, 2021, providing a runway into the first half of 2024. Additionally, the management team was strengthened with key appointments. SNS-101 shows promise against the VISTA immune checkpoint, vital for overcoming challenges in cancer treatment.